The frequency of cancer survival varies depending on any type of cancer you have, as well as the stage at which it is diagnosed. One of the worst cancer statistics anywhere in the world is lung cancer. Published 5-year survival for patients with lung cancer varies from 5% to 16% internationally. One of the reasons that cancer survival rates in a broad sense are so different is that statistical information is not always in the public domain, and each individual study collects and interprets data differently according to the abstract of the study. In other words, every cancer statistic is as unique as you are.
US data points to a 5-year survival rate of up to 16%, although this figure cannot be relied on, since it excludes seventy-five percent of the population, since statistics do not apply to the general population. To make a reliable comparison of mortality from cancer survival rates, is no different from obtaining reliable statistical data for any other disease, data should be collected and analyzed in the same way. (Respiratory Medicine, Volume 100, Issue 9, Pages 1642-1646 C. Butler, K. Darragh, G. Currie, W. Anderson, Respiratory Medicine, Volume 100, Issue 9, Pages 1642-1646). Scared by the statistics or even worse, believing that the statistics can affect how you survive or not cancer.
Face change for cancer survival
Statistics come down to the risks at the end of the day and your risk of getting infected with cancer. In the United States, lung cancer statistics show that it kills more people than those who die from breast cancer, prostate cancer, colon cancer, and cervical cancer in combination. However, this is due to the fact that widespread screening for a certain age for prostate, breast and cervical cancer.
The New England Journal of Medicine, dated October 26, 2006, reported that eighty percent of lung cancer deaths could have been avoided. Screened computed tomography (CT) can detect it at an early stage of stage 1, at this stage it is a treatable cancer. The reason mortality is so gloomy is that by the time most people realize that they have this cancer, it is too advanced to do something.
The initial study was transferred to Weil Cornell Medical Center in New York in 1993 and subsequently expanded to an international study of 38 institutions in 7 countries and became known as the International Lung Cancer Treatment Action Project (I-ELCAP).
Surgery is effective in treating this cancer - this is stage 1, later it is too advanced to be of great importance, and the reason that cancer survival statistics are so dismal is the fact that it is rarely detected at stage 1.
Later studies from 1993 to 2005 in the United States, Europe, Israel, China, and Japan identified 31,567 asymptomatic people at high risk, and then repeated screenings in 27,456 of these people. 484 people were diagnosed with lung cancer, and 412 or 85% of them were Stage 1. Of the 412 patients with stage I, 302 underwent surgical solutions for four weeks, and within this group, the survival rate was 92%.
The estimated 10-year survival rate for 484 participants with lung cancer was more than 80%, which is the highest survival rate ever recorded in a cancer study. In contrast, the statutory survival rate for five years for stage IV may be as low as 5%. Some of them decided not to receive treatment, and all were dead for five years. All participants were at risk of lung cancer because they were all over forty, they either smoked, or smoked, or were exposed to known carcinogens such as asbestos, uranium, radon or beryllium, uranium or radon, or had occupations that exposed them passive smoking.
As and by all means, it is necessary to evaluate the cost-effectiveness of screening compared to the cost of treatment. It costs two times more than to treat lung cancer in the later stages than for the treatment in the first stage. The fee for a screening scan with a low dose of CT is between 200 and 300 dollars. New technologies have made screening more effective, because when CT was new, it was able to yield thirty images, now more than 600 are possible.
To a certain extent, there is resistance to screening lung cancer, because often it is not considered as a disease, but as a reprimand or retribution. There is also little consensus on what constitutes a high-risk population, because although it has been known for over a century that smokers pay for cancer, not all smokers develop lung cancer. However, better genetic pointers will be available in the future, and this will make it easier to predict those at risk, and this will make screening more likely.
